A phase II trial of sorafenib in first-line metastatic urothelial cancer: a study of the PMH Phase II Consortium (Q44951549)

7 December 2017

A phase II trial of sorafenib in first-line metastatic urothelial cancer: a study of the PMH Phase II Consortium (English)

1 reference

7 December 2017

phase II clinical trial

0 references

6

Ian F Tannock

1 reference

7 December 2017

Srikala S Sridhar

1

1 reference

7 December 2017

Eric Winquist

2

1 reference

7 December 2017

Andrea Eisen

3

1 reference

7 December 2017

Sebastien J Hotte

4

1 reference

7 December 2017

Elaine McWhirter

5

1 reference

7 December 2017

Som D Mukherjee

7

1 reference

7 December 2017

Lisa Wang

8

1 reference

7 December 2017

Chantale Blattler

9

1 reference

7 December 2017

John J Wright

10

1 reference

7 December 2017

Malcolm J Moore

11

1 reference

7 December 2017

27 February 2010

1 reference

Investigational New Drugs

7 December 2017

1 reference

7 December 2017

29

1 reference

7 December 2017

1045-1049

1 reference

7 December 2017

5

1 reference

https://scigraph.springernature.com/pub.10.1007/s10637-010-9408-4

7 December 2017

0 references

cites work

Cancer statistics, 2001

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9408-4

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9408-4

Raf kinase as a target for anticancer therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9408-4

Sorafenib in advanced clear-cell renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9408-4

Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9408-4

Sorafenib in advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9408-4

ras Oncogene p21 expression is increased in premalignant lesions and high grade bladder carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9408-4

Review Article: The Role of Ras Superfamily Proteins in Bladder Cancer Progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9408-4

Sunitinib malate is active against human urothelial carcinoma and enhances the activity of cisplatin in a preclinical model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9408-4

VEGF receptor expression and signaling in human bladder tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9408-4

Phase 2 trial of sorafenib in patients with advanced urothelial cancer: a trial of the Eastern Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9408-4

Transcriptional activation of H-ras, K-ras and N-ras proto-oncogenes in human bladder tumors

21 January 2018

1 reference

12 December 2020

Vascular endothelial growth factor is a predictor of relapse and stage progression in superficial bladder cancer

1 reference

12 December 2020

Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy

1 reference

12 December 2020

Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer

1 reference

12 December 2020

Expression of epidermal growth factor receptor in urinary bladder cancer metastases

1 reference

12 December 2020

High-throughput tissue microarray analysis of 3p25 (RAF1) and 8p12 (FGFR1) copy number alterations in urinary bladder cancer

1 reference

12 December 2020

Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study

1 reference

12 December 2020

Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer

1 reference

12 December 2020

Vascular endothelial growth factors and receptors in colorectal cancer: Implications for anti-angiogenic therapy

1 reference

12 December 2020

Phase II study of sorafenib in patients with advanced hepatocellular carcinoma

1 reference

12 December 2020

Different angiogenic pathways characterize superficial and invasive bladder cancer

1 reference

12 December 2020

Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial

1 reference

12 December 2020

10.1007/S10637-010-9408-4

Identifiers

DOI

1 reference

7 December 2017

1 reference